Study on JNJ-64042056 for Preclinical Alzheimer’s Disease in Patients

2 1

What is this study about?

This clinical trial is focused on studying Preclinical Alzheimer’s Disease, a stage of Alzheimer’s where symptoms are not yet noticeable but changes in the brain have begun. The study will evaluate a treatment called JNJ-64042056, which is a type of active immunotherapy designed to target a protein in the brain known as phosphorylated tau. This protein is associated with the development of Alzheimer’s Disease. The trial will compare the effects of JNJ-64042056 with a placebo to see if it can slow down cognitive decline, which refers to the gradual loss of memory and thinking skills.

Participants in the study will receive either the JNJ-64042056 treatment or a placebo through injections. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations. The study will take place over a period of time, with regular assessments to monitor the participants’ cognitive abilities and overall health.

The main goal of the study is to determine if JNJ-64042056 can effectively slow down the progression of cognitive decline in individuals with Preclinical Alzheimer’s Disease. By participating in this study, researchers hope to gather important information that could lead to new treatments for Alzheimer’s Disease in the future.

1 initial visit

Upon joining the study, you will attend an initial visit. During this visit, your eligibility will be confirmed based on specific criteria, such as age and cognitive assessments.

A brain scan will be conducted to check for elevated tau protein levels, which are associated with Alzheimer’s disease.

2 randomization

After eligibility is confirmed, you will be randomly assigned to receive either the study medication, JNJ-64042056, or a placebo. This process is double-blind, meaning neither you nor the study team will know which treatment you are receiving.

3 treatment administration

You will receive the assigned treatment as an injection. The study medication, JNJ-64042056, is administered as a dispersion for injection.

The frequency and dosage of the injections will be determined by the study protocol and communicated to you by the study team.

4 regular follow-up visits

You will attend regular follow-up visits to monitor your health and the effects of the treatment. These visits will include cognitive assessments and other evaluations to track any changes in your condition.

The primary goal is to assess changes in cognitive function over time, using a specific test called the Preclinical AD Cognitive Composite 5 (PACC-5).

5 final assessment

At the end of the study period, which is estimated to be in April 2031, a final assessment will be conducted. This will include a comprehensive evaluation of your cognitive function and overall health.

The results will help determine the effectiveness and safety of the study medication compared to the placebo.

Who Can Join the Study?

Age between 55 and 75 years old at the time of joining the study.
Have elevated brain tau pathology, which means having a specific level of a protein called tau in the brain, as shown by a special brain scan called a tau PET scan.
Have a CDR global score of 0, which means no signs of dementia, at the start of the study.
Have a MMSE score of 27 or higher, which is a test that checks memory and thinking skills. This score may be adjusted based on education level.
Be able to read and write, with at least 5 years of formal education, as confirmed by both the participant and a study partner.

Who Cannot Join the Study?

Patients with any other serious medical condition that might interfere with the study.
Patients who are currently participating in another clinical trial.
Patients who have had a recent major surgery or are planning to have surgery during the study period.
Patients with a history of severe allergic reactions to any medication.
Patients who are unable to comply with the study procedures.
Patients with a history of drug or alcohol abuse.
Patients who are pregnant or breastfeeding.
Patients with a known psychiatric disorder that could interfere with the study.
Patients who have been diagnosed with any form of dementia other than Alzheimer’s Disease.
Patients who have a significant neurological disorder other than Alzheimer’s Disease.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Hospital Clinico San Carlos	Madrid	Spain
Centre Hospitalier Universitaire De Lille	Lille	France
Oncopole Claudius Regaud	Toulouse	France
Katholieke Universiteit te Leuven	Leuven	Belgium
Hospital Universitario De Navarra	Pamplona	Spain

Other Sites

Site Name	City	Country
Hospital Universitari General De Catalunya	Sant Cugat Del Valles	Spain
Universitaetsklinikum Aachen AöR	Aachen	Germany
Algemeen Ziekenhuis Groeninge	Kortrijk	Belgium
Gesundheit Nord gGmbH Klinikverbund Bremen	Bremen	Germany
Fundacio Ace Institut Catala De Neurociencies Aplicades	Barcelona	Spain
Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.	Bonn	Germany
Hospital Universitari De Santa Maria	Lleida	Spain
Region Skane Skanes Universitetssjukhus	Lund	Sweden
Central Institute of Mental Health	Mannheim	Germany
Hospital Clinic De Barcelona	Barcelona	Spain
Karolinska University Hospital	Solna	Sweden
Saarland University Hospital	Homburg	Germany
Hospital Universitario Quironsalud Madrid	Pozuelo De Alarcon	Spain
Jessa Ziekenhuis	Hasselt	Belgium
Centre Hospitalier Universitaire De Nantes	Nantes	France
Fundacio Assistencial De Mutua De Terrassa Fpc	Terrassa	Spain
Hopital Beaujon	Clichy	France
Vrije Universiteit Brussel	Jette	Belgium
Queen Silvia Childrens Hospital – Sahlgrenska University Hospital – Vaestra Goetalandsregionen	Gothenburg	Sweden
Cpfsmikct Uicxmxgzbfxoye Svbdlaygq	Woluwe-Saint-Lambert	Belgium
Bkfydodvvuqob Bouwa Rxoxobry Cluawy	Barcelona	Spain
Upwlzfskat Hozbnygc Cmcqbgd	Cologne	Germany
Uuyxcvo Uimhostawc Hwrnbrqa	Uppsala	Sweden
Cdohto Hdhsefzcnjs Rhnjiuig Ujkbqaqjzahkq Dm Tpgoi	Tours	France
Uuxzlxxnkrnljunskkwhg Moewhrmf Agi	Munster	Germany
Hhbdliqz Dl Lf Spsfj Citc I Snsg Pxk	Barcelona	Spain
Ueulftirby Oy Alzpcpk	Edegem	Belgium

Trial status

Country	Status	Recruitment Start
Belgium	Not recruiting	30.07.2024
France	Not yet recruiting	30.07.2024
Germany	Not recruiting	30.07.2024
Spain	Not yet recruiting	30.07.2024
Sweden	Not recruiting	30.07.2024

Trial locations

Investigated drugs:

JNJ-64042056 is a type of treatment designed to help people with early signs of Alzheimer’s disease. It works by targeting a specific protein in the brain called tau, which is thought to play a role in the development of Alzheimer’s. This treatment aims to slow down the decline in memory and thinking skills that can happen in people with this condition. The goal is to see if this treatment can help maintain cognitive abilities, which are important for daily activities and quality of life.

Preclinical Alzheimer’s Disease – Preclinical Alzheimer’s Disease is an early stage of Alzheimer’s where individuals show no noticeable symptoms of cognitive decline, but biological changes associated with the disease are present in the brain. During this stage, amyloid plaques and tau tangles may begin to form, which are hallmark features of Alzheimer’s pathology. The disease progresses silently, with these changes occurring years or even decades before any clinical symptoms appear. As the disease advances, it may eventually lead to mild cognitive impairment and, later, to more pronounced symptoms of Alzheimer’s Disease. This stage is crucial for research as it offers a window for potential interventions before significant cognitive decline occurs.

Trial ID:

2023-505096-68-00

Protocol code:

64042056ALZ2001

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on JNJ-64042056 for Preclinical Alzheimer’s Disease in Patients

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?